Overview

Efficacy and Safety Study of CD2027 Ointment 3 mcg/g Twice Daily Treatment for Adults With at Least Moderate Atopic Dermatitis

Status:
Completed
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, randomized, double-blind, parallel group study. Efficacy Objectives: To evaluate the efficacy of CD2027 ointment 3 mcg/g applied twice daily over 4 weeks versus its vehicle in adult subjects with at least moderate atopic dermatitis. Safety objective: To evaluate safety of CD2027 ointment 3 mcg/g when applied twice daily over 4 weeks versus its vehicle on 5% - 20% involved BSA (excluding Head/Neck) in adult subjects with at least moderate atopic dermatitis.
Phase:
Phase 2
Details
Lead Sponsor:
Galderma
Galderma R&D